Genzyme moved to buy rating

Genzyme Corp. was upgraded by Merrill Lynch analyst Eric Ende to buy with a $74 price target despite concerns about weak second-quarter earnings. Merrill expects second-half 2006 revenues to be boosted by a weaker dollar, Medicare Part D and a strong Myozyme launch. Shares of the Cambridge, Mass.-based biopharmaceutical company were up 9 cents, or 0.15%, at $60.33 on volume of 2,288,638 shares versus the three-month running average of 2,992,230 shares. (Nasdaq: GENZ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.